Premium
Study: Routine genotyping demonstrates no benefit for antipsychotic outcome
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30701
Subject(s) - medicine , genotyping , antipsychotic , schizophrenia (object oriented programming) , randomized controlled trial , drug , antipsychotic drug , pharmacology , psychiatry , genotype , biology , genetics , gene
Routine genetic testing for two enzymes involved in drug metabolism had no beneficial effect on outcomes from antipsychotic drug treatment when compared with standard monitoring, a randomized clinical trial has found. The results offer no support for routine cytochrome P450 (CYP) testing in patients with schizophrenia, according to the researchers. Study results were published online Dec. 7, 2020, in JAMA Network Open .